Holdings
ProShares Ultra Nasdaq Biotechnology
As of May 31, 2026, ProShares Ultra Nasdaq Biotechnology reported 243 positions worth US$45.5M. Largest: Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated and Amgen Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 25,542 | US$3.43M | −14,362 | May 31, 2026 |
| Vertex Pharmaceuticals Incorporated | 7,657 | US$3.43M | −3,924 | May 31, 2026 |
| Amgen Inc. | 9,803 | US$3.3M | −4,733 | May 31, 2026 |
| Regeneron Pharmaceuticals, Inc. | 3,840 | US$2.36M | −929 | May 31, 2026 |
| Alnylam Pharmaceuticals, Inc. | 4,904 | US$1.48M | −1,197 | May 31, 2026 |
| Revolution Medicines, Inc. | 7,326 | US$1.15M | −1,601 | May 31, 2026 |
| Biogen Inc. | 5,425 | US$1.06M | −1,349 | May 31, 2026 |
| Illumina, Inc. | 5,653 | US$921K | −1,402 | May 31, 2026 |
| United Therapeutics Corporation | 1,620 | US$902K | −368 | May 31, 2026 |
| Royalty Pharma Plc | 15,837 | US$883K | −3,892 | May 31, 2026 |